Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Massachusetts General Hospital
80 participants
Nov 1, 2023
INTERVENTIONAL
Conditions
Summary
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).
Eligibility
Inclusion Criteria3
- -65 years of age
- Diagnosed with BPD or MDE
- Chief complaint of suicidal thoughts and behaviors
Exclusion Criteria9
- Neurological conditions with known structural brain lesion
- Prior neurosurgical procedure
- Metal in the body that is ferromagnetic or metal injury to the eyes
- Epilepsy
- Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt
- Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis)
- Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report
- Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology
- Current pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04130958